Based on prior reports of enhanced NK cell-mediated AML responses associated with NKG2D-ligand induction by HDAC inhibitors (46, 58), we hypothesized that selective enhancement of NKG2D-ligand expression in AML could be achieved pharmacologically and lead to enhanced NKG2D-CAR efficacy in this indication. This evidence concerns the gene KLRK1 and acute myeloid leukemia.